Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-((r)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole
2. Dexilant
3. Dexlansoprazole
4. Lansoprazole, R Isomer
5. Lansoprazole, R-isomer
6. R Lansoprazole
7. R-isomer Lansoprazole
8. R-lansoprazole
9. T 168390
10. T-168390
11. T168390
12. Tak 390
13. Tak 390mr
14. Tak-390
15. Tak-390mr
16. Tak390
17. Tak390mr
1. Hs2s9vk3nh
2. 313640-86-7
3. Unii-hs2s9vk3nh
4. Dtxsid50185290
5. Q27280070
6. 1h-benzimidazole, 2-((r)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-, Hydrate (2:3)
| Molecular Weight | 792.8 g/mol |
|---|---|
| Molecular Formula | C32H34F6N6O7S2 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 19 |
| Rotatable Bond Count | 10 |
| Exact Mass | 792.18345876 g/mol |
| Monoisotopic Mass | 792.18345876 g/mol |
| Topological Polar Surface Area | 177 Ų |
| Heavy Atom Count | 53 |
| Formal Charge | 0 |
| Complexity | 480 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 5 |
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
Proton Pump Inhibitors
Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)
ABOUT THIS PAGE
A DTXSID50185290 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of DTXSID50185290, including repackagers and relabelers. The FDA regulates DTXSID50185290 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. DTXSID50185290 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A DTXSID50185290 supplier is an individual or a company that provides DTXSID50185290 active pharmaceutical ingredient (API) or DTXSID50185290 finished formulations upon request. The DTXSID50185290 suppliers may include DTXSID50185290 API manufacturers, exporters, distributors and traders.
click here to find a list of DTXSID50185290 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A DTXSID50185290 written confirmation (DTXSID50185290 WC) is an official document issued by a regulatory agency to a DTXSID50185290 manufacturer, verifying that the manufacturing facility of a DTXSID50185290 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting DTXSID50185290 APIs or DTXSID50185290 finished pharmaceutical products to another nation, regulatory agencies frequently require a DTXSID50185290 WC (written confirmation) as part of the regulatory process.
click here to find a list of DTXSID50185290 suppliers with Written Confirmation (WC) on PharmaCompass.
DTXSID50185290 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of DTXSID50185290 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right DTXSID50185290 GMP manufacturer or DTXSID50185290 GMP API supplier for your needs.
A DTXSID50185290 CoA (Certificate of Analysis) is a formal document that attests to DTXSID50185290's compliance with DTXSID50185290 specifications and serves as a tool for batch-level quality control.
DTXSID50185290 CoA mostly includes findings from lab analyses of a specific batch. For each DTXSID50185290 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
DTXSID50185290 may be tested according to a variety of international standards, such as European Pharmacopoeia (DTXSID50185290 EP), DTXSID50185290 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (DTXSID50185290 USP).
LOOKING FOR A SUPPLIER?
